The National Institutes of Health has awarded a total of $30 million in funding grants to six research teams to support the development of an HIV cure.
NIH said Wednesday the grant recipients will investigate HIV treatment strategies including immunotherapy, therapeutic vaccines and gene modification as the second batch of awardees under the Martin Delaney Collaboratory program.
“The two greatest challenges remaining in HIV/AIDS research are finding a cure and developing a safe and effective preventive vaccine,” said Anthony Fauci, National Institute of Allergy and Infectious Diseases director.
“A simple, safe and scalable cure for HIV would accelerate progress toward ending the HIV/AIDS pandemic,” he added.
NIH awarded grants for thest research projects:
- Bench to Bed Enhanced Lymphoctye Infusions to Engineer Viral Eradication at George Washington University
- Delaney AIDS Research Enterprise to Cure HIV at the University of California
- defeatHIV: Cell and Gene Therapy for HIV Cure at the Fred Hutchinson Cancer Research Center
- BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy at the Wistar Institute
- Combined Immunologic Approaches to Cure HIV-1 at the Beth Israel Deaconess Medical Center
- Collaboratory of AIDS Researchers for Eradication at the University of North Carolina
Awardees will carry out research work in various laboratories across five continents including Africa, NIH noted.
NIAID established the Martin Delaney Collaboratory program in 2010 to support international HIV cure research efforts and foster collaborations related to HIV treatment.